Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
- RR 0.73 [0.36, 1.47]2 studies · 135 participantsLow